No Current UK Marketing Authorisation Identified No current UK marketing authorisation for a BPC-157 plus TB-500 combination, BPC-157 or TB-500 was identified in the official sources reviewed for this article
DOI: Published online: February 14, 2024 1 Borthwick Diabetes Research Centre, Lister Hospital, Stevenage, UK 2 Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland Corresponding author: Adie Viljoen
doi: 10.1152/ajpcell.1998.275.5.C1365 187
The Glow Stack Composition & Key Research Facts Total blend weight: 70mg lyophilised powder per vial Components: BPC-157 (pentadecapeptide), TB-500 (Thymosin Beta-4 fragment), GHK-Cu (copper tripeptide-1) Primary research focus: Tissue repair signalling pathways, extracellular matrix biology, collagen synthesis, angiogenesis, fibroblast and keratinocyte biology Pathway coverage: ERK1/2, VEGFR2/PI3K/Akt/eNOS (BPC-157)